Syndicate Bio has launched Direct by Syndicate Bio, a genetic testing and precision medicine service designed to deliver actionable insights to patients, providers, and consumers across Africa.
The firm also opened its sequencing laboratory in Lagos, enabling world-class genomic and multi-omics testing powered by AI-delivered locally for Nigeria’s 200 million citizens and the global diaspora.
The Lagos facility is built to set new global standards for precision medicine on the continent. Equipped with next-generation sequencing and advanced molecular workflows, the lab supports clinical-grade testing and research while ensuring faster turnaround times for Nigerian clinicians, researchers, and patients.
Nigeria’s unparalleled ethnic diversity creates unique mutational signatures and drug-metabolism profiles. By integrating genomics, transcriptomics, and metabolomics with AI-driven analysis, Direct by Syndicate Bio will uncover biomarkers tailored to local populations-advancing precision medicine not only in Nigeria but also for millions worldwide who share genetic ancestry with its communities.
The launch event brought together leading stakeholders, including representatives from the National Institute for Cancer Research and Treatment (NICRAT), Lakeshore Cancer Center, Redus Center for Digestive Health, Beacon Health, Healthtracka, Society for Family Health, and Atlantis Pediatric Hospital.
Direct by Syndicate Bio is offering testing of 300+ genes, including BRCA1/2 and others linked to breast, ovarian, pancreatic, prostate, and colorectal cancers, over 90 inherited disorders across cardiovascular, hematological, metabolic, neurodevelopmental, ophthalmological, and immune system categories, over 80 genes related to nutrition, metabolism, fitness, skin health, immunity, sleep, and lifestyle traits, comprehensive solid and myeloid tumor profiling for targeted cancer treatment decisions.
It’s also offering early, safe assessment of fetal health, drug selection and dosing guided by individual genetic profiles, Sickle cell disease, thalassemia, G6PD deficiency, and hemophilia A/B included as standard and next-generation sequencing ensures comprehensive results in the absence of large African genomic reference datasets.
Reports are delivered in a clinician-ready format, supported by genetic counselling, with strict adherence to quality control, data protection, and privacy standards.
To accelerate adoption, Syndicate Bio has established the Direct Nigeria Precision Medicine Network (DNPMN) in partnership with leading institutions. The network will convene a multidisciplinary tumor board to enable local and international case collaboration, second opinions, and knowledge exchange.
Key partners include Lakeshore Cancer Center, Redus Center for Digestive Health and Roswell Park Comprehensive Cancer Center (USA).
Through DNPMN, patients and at-risk families will gain access to personalized prevention and intervention strategies, including interventional endoscopies and risk-reducing surgeries, guided by genomic insights.
